Pronóstico del mercado europeo de partículas similares a virus hasta 2028: impacto de COVID-19 y análisis regional por tipo de producto (hepatitis, cáncer/VPH y enfermedad de Gaucher), fuente (levadura, células de insectos, plantas y otros) y aplicación (vacunas y Terapéutica)
Introducción al mercado
Europa está compuesta por cinco países destacados: Alemania, Francia, Reino Unido e Italia. y España. El mercado también comprende el resto de países de Europa. El mercado europeo de partículas similares a virus está experimentando un mayor crecimiento debido a la aprobación de nuevos productos por parte de los organismos autorizados. Por ejemplo, la primera vacuna autorizada contra la malaria basada en VLP, \"Mosquirix\", fue aprobada por los reguladores europeos. Además, países como el Reino Unido, Alemania, Francia, Italia y España son los principales contribuyentes que impulsan la demanda de productos con partículas similares a virus en Europa.
Según el Según el informe de la Organización Mundial de la Salud (OMS), actualmente todos los países de Europa se enfrentan a una amenaza real de COVID-19. El ritmo de transmisión del virus en los 53 países de la Región Europea de la OMS es motivo de preocupación. Para controlar la transmisión, los países de Europa están llevando a cabo campañas de vacunación en varias etapas. En Europa, actualmente se están desarrollando y ensayando clínicamente varias vacunas contra el COVID-19, en países como el Reino Unido, Alemania y Rusia. Entre ellas, hay tres vacunas en el Reino Unido, tres vacunas en Alemania y dos en Rusia. Entre estas vacunas, hay una vacuna inactivada, dos de subunidades proteicas, tres vacunas de vectores virales y dos vacunas de ácido nucleico. Para combatir el coronavirus en la región europea, Europa en su conjunto ha realizado esfuerzos constantes para impulsar el desarrollo de vacunas. El informe Bruegel afirma que, antes de la pandemia de COVID-19, la UE anunció una financiación de casi 500 millones de dólares para la investigación de vacunas a través del programa de investigación Horizonte 2020 durante el período 2014-2020. Además, para combatir el COVID-19, la UE ha ofrecido fondos de emergencia para apoyar la investigación y el desarrollo de diagnósticos, terapias y vacunas. Inicialmente, 10 millones de dólares aumentaron posteriormente a 47,5 millones de dólares y se asignaron a proyectos de investigación para responder a la pandemia de COVID-19. Además, la inauguración del Instituto Europeo de Tecnología de la Salud en abril de 2020 fue una convocatoria a los socios del EIT para que enviaran propuestas de proyectos COVID-19 con una implementación sólida y financiación de cada proyecto.
< strong>Descripción general y dinámica del mercado
Se espera que el mercado de partículas similares a virus en Europa crezca desde 1.302,03 millones de dólares en 2021 a US$ 2.203,61 millones para 2028; se estima que crecerá a una tasa compuesta anual del 7,8% de 2021 a 2028. Las vacunas forman uno de los segmentos importantes de la industria farmacéutica. Tienen una amplia aplicación en la inmunización de humanos y animales contra infecciones comunes. Las empresas que operan en los mercados farmacéuticos y biofarmacéuticos se centran continuamente en innovaciones y desarrollos de productos para mantener la competencia en el mercado. Por ejemplo, los actores del mercado han estado invirtiendo significativamente en el desarrollo de vacunas contra COVID-19 y estudios relacionados con VLP. Los desarrollos activos de las empresas de ciencias biológicas, junto con el apoyo gubernamental para los mismos, están contribuyendo al crecimiento del mercado de VLP.
Segmentos de mercado clave
En términos de tipo de producto, el segmento de hepatitis representó la mayor parte del mercado europeo de partículas similares a virus en 2021. En términos de fuente, el El segmento de levadura representó la mayor participación del mercado europeo de partículas similares a virus en 2021. En términos de aplicación, el segmento de vacunas tuvo una mayor participación de mercado en el mercado de partículas similares a virus en 2021.
Principales fuentes y empresas enumeradas
Algunas de las principales fuentes primarias y secundarias a las que se hace referencia para preparar este informe En el mercado europeo de partículas similares a virus se encuentran sitios web de empresas, informes anuales, informes financieros, documentos gubernamentales nacionales y bases de datos estadísticas, entre otros. Las principales empresas que figuran en el informe son Merck & Co., Inc.; GlaxoSmithKline plc.; Pfizer Inc.; Sanofi; Serum Institute of India Pvt. Limitado. Limitado.; BHARAT BIOTECNOLOGÍA; LG Química; y Dynavax Technologies, entre otros.
Informe de razones para comprar
- Comprender el panorama del mercado europeo de partículas similares a virus e identificar los segmentos del mercado que tienen más probabilidades de garantizar un fuerte retorno
- Manténgase a la vanguardia al comprender el panorama competitivo en constante cambio para el mercado europeo de partículas similares a virus
- Planifique eficientemente M& ;A y acuerdos de asociación en el mercado europeo de partículas similares a virus mediante la identificación de segmentos de mercado con las ventas probables más prometedoras
- Ayuda a tomar decisiones comerciales informadas a partir de un análisis perspicaz y completo del desempeño del mercado de varios segmentos del mercado europeo de partículas similares a virus
- Obtener un pronóstico de ingresos de mercado para varios segmentos desde 2021-2028 en la región de Europa.
Segmentación del mercado europeo de partículas similares a virus
Mercado europeo de partículas similares a virus: por tipo de producto
- Hepatitis
- Cáncer/VPH
- Enfermedad de Gaucher
Mercado europeo de partículas similares a virus: por fuente
- Levadura
- Célula de insecto
- Planta
- Otros
Mercado europeo de partículas similares a virus: por Aplicación
- Vacunas
- Terapéutica
Mercado europeo de partículas similares a virus: por país
- Alemania
- Francia
- Reino Unido
- Italia
- España
- Resto de Europa
Mercado europeo de partículas similares a virus: empresas mencionadas
- Merck & Co., Inc. ; &n bsp ;
- GlaxoSmithKline plc.
- Pfizer Inc. ; &n bsp ; &n bsp ;
- Sanofi ; &n bsp ; &n bsp ;
- Serum Institute of India Pvt. Ltd. Ltd.
- BHARAT BIOTECH ; &n bsp ;
- LG Chem ; ;
- Tecnologías Dynavax
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Virus-like Particles Market – By Product Type
1.3.2 Europe Virus-like Particles Market – By Source
1.3.3 Europe Virus-like Particles Market – By Application
1.3.4 Europe Virus-like Particles Market – By Country
2. Europe Virus-like Particles Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Virus-like Particles Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. Europe Virus-like Particles Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Raising Prevalence of Infectious Viral Diseases
5.1.2 The Growing Role of Virus-Like Particles in Therapeutic Developments and Studies
5.2 Market Restraints
5.2.1 Access of Alternative Technologies for Viral Vaccine Production
5.3 Market Opportunities
5.3.1 Boosting Potential Applications in Therapeutics and Diagnostics
5.4 Future Trends
5.4.1 Ongoing Demand for Innovative and Effective Products
5.5 Impact Analysis
6. Europe Virus-like Particles Market Analysis
6.1 Europe Virus-like Particles Market Revenue Forecast and Analysis
7. Europe Virus-like Particles Market Analysis – by Product Type
7.1 Overview
7.2 Europe Virus-like Particles Market, by Product Type, 2021 & 2028 (%)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
7.4 Cancer/ Human Papillomavirus (HPV)
7.4.1 Overview
7.4.2 Cancer/HPV: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
7.5 Gaucher Disease
7.5.1 Overview
7.5.2 Gaucher Disease: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8. Europe Virus-like Particles Market Analysis – By Source
8.1 Overview
8.2 Europe Virus-like Particles Market Share, by Source, 2021 & 2028 (%)
8.3 Yeast
8.3.1 Overview
8.3.2 Yeast: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.4 Plant
8.4.1 Overview
8.4.2 Plant: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.5 Insect Cell
8.5.1 Overview
8.5.2 Insect Cell: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
9. Europe Virus-like Particles Market Analysis – By Application
9.1 Overview
9.2 Europe Virus-like Particles Market Share, by Application, 2021 & 2028 (%)
9.3 Vaccines
9.3.1 Overview
9.3.2 Vaccine: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
9.4 Therapeutics
9.4.1 Overview
9.4.2 Therapeutics: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10. Europe Virus-like Particles Market – Country Analysis
10.1 Overview
10.1.1 Europe: Virus-like Particles Market, by Country, 2021 & 2028(%)
10.1.1.1 Germany: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 Germany: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.4 Germany: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.5 Germany Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.2 France: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 France: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 France: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.4 France: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.5 France Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.3 UK: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 UK: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 UK: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.4 UK: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.5 UK Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.4 Italy: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.3 Italy: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.4 Italy: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.5 Italy Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.5 Spain: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.3 Spain: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.4 Spain: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.5 Spain Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.6 Rest of Europe: Virus-Like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.3 Rest of Europe: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.4 Rest of Europe: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.5 Rest of Europe Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
11. Impact Of COVID-19 Pandemic on Europe Virus-like Particles Market
11.1 Impact Assessment of COVID-19 Pandemic
12. Europe Virus-like Particles Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Dynavax Technologies
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sanofi
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Serum Institute of India Pvt. Ltd.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 BHARAT BIOTECH
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 LG Chem
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Virus-like Particles Market, Revenue and Forecast to 2028 (US$ Million)
Table 2. Germany: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 4. Germany Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 5. France: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. France: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 7. France Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 8. UK: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. UK: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 10. UK Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 11. Italy: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Italy: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 13. Italy Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 14. Spain: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. Spain: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 16. Spain Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Europe: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Europe: Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of Europe Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 20. Organic Developments Done by Companies
Table 21. Inorganic Developments Done by Companies
Table 22. Glossary of Terms: Virus-like Particles Market
LIST OF FIGURES
Figure 1. Europe Virus-like particles Market Segmentation
Figure 2. Europe Virus-like particles Market Segmentation, By Country
Figure 3. Europe Virus-like Particles Market Overview
Figure 4. Hepatitis Held the Largest Share of the Product Type Segment in Europe Virus-like particles Market
Figure 5. The UK to Show Significant Growth during Forecast Period
Figure 6. Europe Virus-like Particles Market, Industry Landscape
Figure 7. Europe PEST Analysis
Figure 8. Europe Virus-like Particles Market: Impact Analysis of Drivers and Restraints
Figure 9. Europe Virus-like Particles Market– Revenue Forecast and Analysis to 2028
Figure 10. Europe Virus-like Particles Market, by Product Type, 2021 & 2028 (%)
Figure 11. Hepatitis: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 12. Cancer/HPV: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 13. Gaucher Disease: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 14. Europe Virus-like Particles Market Share, by Source, 2021 & 2028 (%)
Figure 15. Yeast: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Plant: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Insect Cell: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Others: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Europe Virus-like Particles Market Share, by Application, 2021 & 2028 (%)
Figure 20. Vaccine: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Therapeutics: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Europe: Virus-like Particles Market, by Key Country – Revenue (2021) (USD Million)
Figure 23. Europe: Virus-like Particles Market, by Country, 2021 & 2028 (%)
Figure 24. Germany: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. France: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. UK: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Italy: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Spain: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Rest of Europe: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Impact of COVID-19 Pandemic in European Country Markets
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- Dynavax Technologies
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe virus-like particles market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe virus-like particles market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the virus-like particles market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution